Navigation Links
Quest for better treatment for effects of menopause

This release is available in Spanish.

During menopause, lack of oestrogens increases the risk of suffering cardiovascular diseases. For her doctoral thesis, University of the Basque Country researcher, Ainhoa Ruiz del Agua, studied the effects of substitute treatments and the genetic factors influencing the response to these therapies.

Menopause is a natural period in the ageing process of a woman. On ceasing the ovary function, the body gradually stops producing eggs and female sex hormones (amongst these being oestrogen and progesterone), responsible for regulating the menstrual cycle. Lack of oestrogens increases the risk of very important diseases with respect to premenopause, amongst these being osteoporosis and illnesses related to the cardiovascular system. Amongst these heart diseases atherosclerosis is the most important, being an illness characterised by the presence of plaques full of lipids (fats) along the walls of the arteries, and which restricts the blood flow, causing high blood pressure. If these plaques break, the result is a thrombosis that can block the artery, causing, amongst other things, heart attack.

To slow down the natural drop in oestrogen level and thus prevent associated problems, substitutive hormonal therapies are prescribed during the menopause, either orally or subcutaneously (with patches), as well as by treatments based on substances that modulate the oestrogen receptor, amongst these being raloxifene. However, the effects of these therapies are disputed, given that there are no definitive conclusions about their usefulness: research carried out to date shows their efficacy in preventing osteoporosis, but it has not been clarified if they are capable of reducing the risk of contracting heart disease. Moreover, the response amongst different women to the same treatment can vary according to environmental factors, population, diet and, of course, as a function of genetic factors.

Ms Ainhoa Ruiz del Aguas PhD thesis addressed these questions when she recently defended it at the University of the Basque Country (UPV/EHU): Oxidative stress biomarkers during postmenopause: effect of substitutive treatments. Dr Ruiz del Agua is a biochemistry graduate who is currently working as a researcher contracted by the Department of Physiology in the Faculty of Medicine and Odontology of the UPV/EHU. Her work was led by Ms Mara Begoa Ruiz Larrea and Mr Jos Ignacio Ruiz Sanz.

Treatment with diverse effects

The principal aim of the research is to determine the effect of substitutive treatments normally administered during postmenopause. Moreover, it aims to define the genetic markers that condition the response to each of the treatments. To this end, Doctor Ruiz del Agua analysed the response by a group of women from Bizkaia to two treatments: on the one hand, to raloxifene and, on the other, to a substitutive hormonal treatment combining estradiol (a type of oestrogen) and progesterone (another female sex hormone).

The conclusions of Doctor Ruiz del Aguas thesis point to raloxifene, while increasing the antioxidant activity of an enzyme known as arilesterase, which is beneficial, has a neutral effect on the cardiovascular system, given that it does not modifiy other cardiovascular risk markers, nor the characteristics of LDL (bad cholesterol) particles.

As regards combined hormonal therapy, Ruiz del Agua points to two main conclusions: it reduces one of the cardiovascular risk markers studied, which is beneficial, but it also reduces antioxidant activity of the serum, which means an adverse effect on the endothelial function (which avoids blood clots forming) and on the balance necessary between oxidant and antioxidant substances.

Genetic factors determining response to treatment

On the one hand, Doctor Ruiz del Agua states that the response to the treatments studied depends on the genetic burden of each patient, this response being favourable or otherwise, depending on the genetic variables carried by the women for the genes analysed.

In the case of hormonal therapies, carriers of the GG genotype (a combination highly frequent in the mpo gene) undergo a drop in the antioxidant activity of the serum, which means, in this sense, a favourable response to the treatment. In the case of raloxifene, only those women who, because of their genetic burden, are disfavoured for the antioxidant activity of arilesterase, gain benefit thanks to the treatment.

In short, this PhD presented at the UPV/EHU shows that certain aspects of treatments employed in postmenopausic women can be approached from an analysis of genetic polymorphisms, a fact which will contribute to the design of more personalised therapies for their application in postmenopause.


Contact: Alaitz Ochoa de Eribe
Elhuyar Fundazioa

Related biology news :

1. Conquest of land began in shark genome
2. UNC study questions FDA genetic-screening guidelines for cancer drug
3. TAU scientists probe deep questions aboard EcoOceans environmental research ship
4. New research on structure of bones raises questions for treatment of osteoporosis
5. Sticky questions tackled in gecko research
6. Computer-based tool aids research, helps thwart questionable publication practices
7. UA-led research team awarded $50 million to solve plant biologys grand challenge questions
8. Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology
9. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
10. A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago
11. Answer to troublesome question of why some genetic assoc. studies have failed replication attempts
Post Your Comments:
(Date:10/29/2015)... MINNETONKA, Minn. , Oct. 29, 2015   ... that supports the entire spectrum of clinical research, is ... the Minnesota High Tech Association (MHTA) as one of ... in the "Software – Small and Growing" category. The ... and individuals who have shown superior technology innovation and ...
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
(Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) ... Pierre Laurin , President and Chief Executive Officer of ... Piper Jaffray 27 th Annual Healthcare Conference to be ... 2015. st , at 8.50am (ET) and ... the day. The presentation will be available live via a ...
(Date:11/24/2015)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... and chief executive officer, will present at the 27 th ... New York City . The presentation will be ... at 9:30 a.m. EST. and go ... least 15 minutes prior to the presentation to allow for ...
(Date:11/24/2015)... According to two new studies, fewer men are having PSA ... doctors, scientists, and public health experts have been pushing for ... being done, will there be more men dying of ... "Despite the efforts made in regards to early detection for ... of death in men, killing approximately 27,500 men this year. ...
(Date:11/23/2015)... 23, 2015 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the second quarter ... 30, 2015. --> --> ... Revenues for the second quarter of fiscal 2016 increased ...
Breaking Biology Technology: